NRX Pharma gains as FDA allows human trials for UTI drug

NRX Pharmaceuticals

18/12/2023 13:06

** Shares of drug developer NRx Pharmaceuticals  NRXP.O 
rise 25.2% to $0.42 premarket
    ** U.S. FDA allows company to start human trials for
investigational drug as a potential treatment for complicated
urinary tract infections 
    ** The drug, NRX-101, is also being developed for suicidal
treatment-resistant bipolar depression and post-traumatic stress
disorder
    ** Up to Friday's close, stock down 69.5% YTD

 (Reporting by Puyaan Singh and Pratik Jain in Bengaluru)
 ((Puyaan.Singh@thomsonreuters.com;))